Table 4:
Demographic and clinicopathologic data stratified by the presence or absence of a rhabdomyosarcoma component
| No rhabdomyosarcoma component present (n=97) |
Rhabdomyosarcoma component present (n=31) |
p-value | |
|---|---|---|---|
| Median age, years (range) | 66 (36–91) | 70 (51–87) | 0.06 |
| Median BMI, kg/m2 (range) | 29.1 (17.3–73.3) | 30.4 (21.3–62.8) | 0.45 |
| Race | 0.24 | ||
| White | 70 (72.2%) | 21 (65.6%) | |
| Black | 24 (24.7%) | 9 (29.0%) | |
| Asian | 0 (0%) | 1 (3.2%) | |
| Other or unknown | 3 (3.1%) | 0 (0%) | |
| Prior Treatment History | |||
| Prior Pelvic Radiation | 1 (1.1%) | 0 (0%) | 1.00 |
| Prior Chemotherapy | 4 (4.4%) | 2 (6.5%) | 0.65 |
| Prior Tamoxifen Use | 8 (44.4%) | 4 (50%) | 1.00 |
| FIGO Stage | 0.85 | ||
| IA | 69 (71.1%) | 21 (67.7%) | |
| IB | 17 (17.5%) | 6 (19.3%) | |
| II | 11 (11.3%) | 4 (12.9%) | |
| Deep myometrial invasion (≥ 50%) | 24 (26.7%) | 6 (22.2%) | 0.80 |
| Median tumor size, cm (range) (n=77) | 6.0 (0.3–14.0) | 9.0 (4.0–21.0) | 0.003 |
| Lymphovascular space invasion present (n=127) | 39 (40.6%) | 13 (41.9%) | 0.90 |
| Majority sarcoma component (≥ 50%) (n=67) | 15 (34.1%) | 20 (87.0%) | < 0.001 |
| Overall adjuvant treatment approach | 0.85 | ||
| None | 35 (36.1%) | 13 (41.9%) | |
| Cuff brachytherapy | 15 (15.5%) | 5 (16.1%) | |
| Whole pelvic radiation therapy (with or without VBT) | 16 (16.5%) | 3 (9.7%) | |
| VBT with adjuvant chemotherapy | 15 (15.5%) | 4 (12.9%) | |
| Pelvic RT with adjuvant chemotherapy | 7 (7.2%) | 4 (12.9%) | |
| Chemotherapy alone | 9 (9.3%) | 2 (6.5%) | |